PT - JOURNAL ARTICLE AU - MAKOTO KAWAMOTO AU - KEIGO OZONO AU - YASUHIRO OYAMA AU - AKIO YAMASAKI AU - YOSHINAO ODA AU - HIDEYA ONISHI TI - The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer <em>In Vitro</em> DP - 2018 Apr 01 TA - Anticancer Research PG - 1979--1986 VI - 38 IP - 4 4099 - http://ar.iiarjournals.org/content/38/4/1979.short 4100 - http://ar.iiarjournals.org/content/38/4/1979.full SO - Anticancer Res2018 Apr 01; 38 AB - We previously reported that brain-derived neurotrophic factor (BDNF)/neurotrophic receptor tyrosine kinase 2 (NTRK2/TRKB) signaling contributes to induction of malignant phenotype of gallbladder cancer (GBC). Recently, pan-TRK inhibitors have been evaluated and their dramatic clinical activity is being shown for a variety of cancer types harboring an NTRK rearrangement in phase I trials. ONO-7579 is an oral pan-TRK inhibitor currently under investigation in phase I/II clinical trial for TRK-rearranged solid tumors. In this study, we evaluated the anticancer effect of ONO-7579 using GBC cells with or without KRAS mutant, NOZ, TYGBK-1. Our study showed that ONO-7579 had a suppressive effect on GBC proliferation in TYGBK-1, and on invasive potential and vascular endothelial growth factor expression in TYGBK-1 and NOZ. Our data indicated that ONO-7579 could be a promising treatment option for patients with GBC.